Role of antihypertensive therapy with angiotensinconverting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention

Robert Talbert

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To review the available literature on the effects of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs) or combinations of these agents on stroke outcomes in hypertensive patients. Data sources: A Medline search was conducted using the search terms stroke and antihypertensives, calcium channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers from 1985 to August 17, 2009. Study selection: Randomized controlled clinical trials with at least 400 randomized patients were selected if at least one of the treatment arms used a CCB, ACEI, or ARB to evaluate stroke outcomes in hypertensive patients. Data synthesis: The prevalence of stroke is high in the United States, accounting for approximately 150,000 deaths per year. Early identification and treatment of hypertension to quickly achieve blood pressure reduction is critical in the prevention of stroke. Many trials have provided evidence that CCBs, ACEIs, and ARBs are effective in stroke prevention. Most patients require two or more antihypertensive drugs to achieve blood pressure goals. Because of their complementary actions, combination antihypertensive therapy with a renin-angiotensin-aldosterone system (RAAS) blocker and a CCB may help reduce stroke incidence to a greater extent than either of the monotherapies. Conclusion: A growing body of clinical trial data suggest that aggressive combination antihypertensive therapy, including a RAAS blocker and CCB, may help reduce stroke incidence. Fixed-dose combination therapy is an important consideration in optimizing blood pressure control and patient adherence to therapy in stroke prevention.

Original languageEnglish (US)
JournalJournal of the American Pharmacists Association
Volume50
Issue number5
DOIs
StatePublished - 2010

Fingerprint

Angiotensin Receptor Antagonists
Calcium Channel Blockers
Enzyme Inhibitors
Antihypertensive Agents
Stroke
Angiotensin-Converting Enzyme Inhibitors
Blood pressure
Angiotensins
Aldosterone
Renin
Therapeutics
Renin-Angiotensin System
Blood Pressure
Pressure control
Information Storage and Retrieval
Incidence
Patient Compliance
Randomized Controlled Trials
Clinical Trials
Hypertension

Keywords

  • Antihypertensive agents
  • Blood pressure
  • Hypertension
  • Pharmacotherapy
  • Stroke prevention and treatment

ASJC Scopus subject areas

  • Pharmacy
  • Pharmacology
  • Pharmacology (nursing)
  • Medicine(all)

Cite this

@article{cb7aa75bd34049f08222de04728e1f11,
title = "Role of antihypertensive therapy with angiotensinconverting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention",
abstract = "Objective: To review the available literature on the effects of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs) or combinations of these agents on stroke outcomes in hypertensive patients. Data sources: A Medline search was conducted using the search terms stroke and antihypertensives, calcium channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers from 1985 to August 17, 2009. Study selection: Randomized controlled clinical trials with at least 400 randomized patients were selected if at least one of the treatment arms used a CCB, ACEI, or ARB to evaluate stroke outcomes in hypertensive patients. Data synthesis: The prevalence of stroke is high in the United States, accounting for approximately 150,000 deaths per year. Early identification and treatment of hypertension to quickly achieve blood pressure reduction is critical in the prevention of stroke. Many trials have provided evidence that CCBs, ACEIs, and ARBs are effective in stroke prevention. Most patients require two or more antihypertensive drugs to achieve blood pressure goals. Because of their complementary actions, combination antihypertensive therapy with a renin-angiotensin-aldosterone system (RAAS) blocker and a CCB may help reduce stroke incidence to a greater extent than either of the monotherapies. Conclusion: A growing body of clinical trial data suggest that aggressive combination antihypertensive therapy, including a RAAS blocker and CCB, may help reduce stroke incidence. Fixed-dose combination therapy is an important consideration in optimizing blood pressure control and patient adherence to therapy in stroke prevention.",
keywords = "Antihypertensive agents, Blood pressure, Hypertension, Pharmacotherapy, Stroke prevention and treatment",
author = "Robert Talbert",
year = "2010",
doi = "10.1331/JAPhA.2010.09234",
language = "English (US)",
volume = "50",
journal = "Journal of the American Pharmacists Association",
issn = "1544-3191",
publisher = "American Pharmacists Association",
number = "5",

}

TY - JOUR

T1 - Role of antihypertensive therapy with angiotensinconverting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention

AU - Talbert, Robert

PY - 2010

Y1 - 2010

N2 - Objective: To review the available literature on the effects of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs) or combinations of these agents on stroke outcomes in hypertensive patients. Data sources: A Medline search was conducted using the search terms stroke and antihypertensives, calcium channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers from 1985 to August 17, 2009. Study selection: Randomized controlled clinical trials with at least 400 randomized patients were selected if at least one of the treatment arms used a CCB, ACEI, or ARB to evaluate stroke outcomes in hypertensive patients. Data synthesis: The prevalence of stroke is high in the United States, accounting for approximately 150,000 deaths per year. Early identification and treatment of hypertension to quickly achieve blood pressure reduction is critical in the prevention of stroke. Many trials have provided evidence that CCBs, ACEIs, and ARBs are effective in stroke prevention. Most patients require two or more antihypertensive drugs to achieve blood pressure goals. Because of their complementary actions, combination antihypertensive therapy with a renin-angiotensin-aldosterone system (RAAS) blocker and a CCB may help reduce stroke incidence to a greater extent than either of the monotherapies. Conclusion: A growing body of clinical trial data suggest that aggressive combination antihypertensive therapy, including a RAAS blocker and CCB, may help reduce stroke incidence. Fixed-dose combination therapy is an important consideration in optimizing blood pressure control and patient adherence to therapy in stroke prevention.

AB - Objective: To review the available literature on the effects of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs) or combinations of these agents on stroke outcomes in hypertensive patients. Data sources: A Medline search was conducted using the search terms stroke and antihypertensives, calcium channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers from 1985 to August 17, 2009. Study selection: Randomized controlled clinical trials with at least 400 randomized patients were selected if at least one of the treatment arms used a CCB, ACEI, or ARB to evaluate stroke outcomes in hypertensive patients. Data synthesis: The prevalence of stroke is high in the United States, accounting for approximately 150,000 deaths per year. Early identification and treatment of hypertension to quickly achieve blood pressure reduction is critical in the prevention of stroke. Many trials have provided evidence that CCBs, ACEIs, and ARBs are effective in stroke prevention. Most patients require two or more antihypertensive drugs to achieve blood pressure goals. Because of their complementary actions, combination antihypertensive therapy with a renin-angiotensin-aldosterone system (RAAS) blocker and a CCB may help reduce stroke incidence to a greater extent than either of the monotherapies. Conclusion: A growing body of clinical trial data suggest that aggressive combination antihypertensive therapy, including a RAAS blocker and CCB, may help reduce stroke incidence. Fixed-dose combination therapy is an important consideration in optimizing blood pressure control and patient adherence to therapy in stroke prevention.

KW - Antihypertensive agents

KW - Blood pressure

KW - Hypertension

KW - Pharmacotherapy

KW - Stroke prevention and treatment

UR - http://www.scopus.com/inward/record.url?scp=79952795492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952795492&partnerID=8YFLogxK

U2 - 10.1331/JAPhA.2010.09234

DO - 10.1331/JAPhA.2010.09234

M3 - Article

C2 - 20833609

AN - SCOPUS:79952795492

VL - 50

JO - Journal of the American Pharmacists Association

JF - Journal of the American Pharmacists Association

SN - 1544-3191

IS - 5

ER -